About ISAAR
Past ISAAR s
ISAAR 2007
ISAAR 2005
ISAAR 2003
ISAAR 2001
ISAAR 1999
ISAAR 1997
Photos of ISAAR
 
Past ISAARs
 
ISAAR 2005  
5th International Symposium on Antimicrobial Agents and Resistance
April 27~29, 2005
COEX Center, Seoul, Korea
 
April 28 (THU)
A
Resistance in Gram-positive cocci : pneumococci and enterococci
Speakers
A-1
Global epidemiology of pneumococcal resistance Jae-Hoon Song (Korea)
A-2
Molecular mechanisms of resistance in Streptococcus pneumoniae:
will MICs creep ever higher?		 Donald Low (Canada)
A-3
Epidemiology and mechanisms of glycopeptide resistance
in enterococci		 Robin Patel (USA)
A-4
Resistance to new anti-enterococcal agents Walter Wilson (USA)

B

 Antimicrobial resistance in Gram-negative bacilli Speakers
B-1 Changing ESBLs: what are CTX enzymes, and where did they
come from?
 David Livermore (U.K.)
B-2 Metallo-beta-lactamases and other carbapenemases:
will they become common?
 		Kyungwon Lee (Korea)
B-3 Fluoroquinolone resistance : epidemiology and mechanism
 David Hooper (USA)
B-4 Pan-resistant non-fermenters: an emerging threat Jean-Claude Pechere
(Switzerland)
C
 Detection of antimicrobial resistance in the clinical microbiology lab
Speakers
C-1 Can we have international breakpoints?:
CLSI (NCCLS) perspectives		 Mary Jane Ferraro
(USA)
C-2 Can we have international breakpoints?:
EUCAST perspectives		 Johan W. Mouton
(The Netherlands)
C-3 Molecular detection of antimicrobial resistance in the routine laboratory Frank Cockerill (USA)
C-4 Antifungal susceptibility testing: issues & controversies Thomas Patterson
(USA)
D
 Development of novel antibiotics by novel technology Speakers
D-1 Development of novel antibiotics: hopes and despair
 Robert Moellering (USA)
D-2 Development of novel antibiotics: industrial perspectives? Steven Projan (USA)
D-3 Genomics and antibacterial discovery: the successes and challenges
 David Payne (USA)
E
 Multidrug-resistant tuberculosis : a global challenge Speakers
E-1 The epidemiology of multi-drug resistant TB Thelma Tupasi
(The Philippines)
E-2 Detection of mycobacterial resistance Frank Cockerill (USA)
E-3 TB Control Worldwide : Situation and Problems Mario C. Raviglione
(Switzerland)
E-4 Treatment of multidrug-resistant tuberculosis O Jung Kwon (Korea)
F
 Treatment options for nosocomial infections (Interactive session) Speakers
F-1 Case: community-acquired pneumonia Donald Low (Canada)
F-2 Case: infective endocarditis Walter Wilson (USA)
F-3 Case : urinary tract infection
 Visanu Thamlikitkul
(Thailand)
F-4 Case: bacterial meningitis Keith Klugman (USA)
G
 Resistance in Gram-positive cocci : staphylococci Speakers
G-1 Community-acquired MRSA: what, why, and where? Robert Daum (USA)
G-2 Genetics and evolution of hospital and community MRSA
 Teruyo Ito (Japan)
G-3 Epidemiology and clinical implications of glycopeptide-resistant
S. aureus
 Michael Jacobs (USA)
G-4 Detection and relevance of hetero-VISA Mary Jane Ferraro
(USA)
H
 Novel vaccines Speakers
H-1

Old wine in a new bottle: IVI s programs to introduce new
vaccines against bacterial enteric pathogens in developing countries

 John Clemens (USA)
H-2 Anthrax vaccine adsorbed (AVA)
: a human reactogenicity and immunogenicity clinical trial
 		Bradley Perkins (USA)
H-3 HIV/ AIDS vaccine : is there any hope? Donald Sutherland
 (WHO)
I
 Treatment options for community-acquired infections
(Interactive session)		 Speakers
I-1 Case: infections caused by VRE
 Robin Patel (USA)
I-2 Case: pandrug-resistant Acinetobacter baumannii
 		Po-Ren Hsueh
(Chinese Taipei)
I-3 Case : nosocomial pneumonia
Ki-Suck Jung (Korea)
I-4 Case: complicated fungal infections Thomas Patterson
(USA)
April 29 (FRI)
J
 Anti-retroviral therapy in the era of resistance Speakers
J-1 Antiretroviral resistance and HIV/AIDS in developing countries Adeeba Kamarulzaman
(Malaysia)
J-2 HIV drug resistance: a major challenge in antiviral therapy of AIDS Hiroaki Mitsuya (Japan)
J-3 Antiretroviral therapy in Africa-2005 Merle Sande (USA)
J-4 New antiretroviral drugs Zelalem Temesgen (USA)
K
 Pharmacodynamic application of antimicrobial treatment Speakers
K-1 What pharmacodynamic parameters for which drugs? In Jin Jang (Korea)
K-2 Pharmacodynamics of new antimicrobials Johan W. Mouton
(The Netherlands)
K-3 Can we model the pharmacodynamics of antibiotic combinations? John Turnidge (Australia)
*Presented by Keryn
Christiansen (Australia)
K-4 Antibiotic tissue concentration: what really matters Craig Rayner (Australia)
L
 Pediatric issues Speakers
L-1 Community-acquired pneumonia in children Nancy Henry (USA)
L-2 Enteric infections Cheng-Hsun Chiu
(Chinese Taipei)
L-3 Hemophilus type B vaccination
 Robert Daum (USA)
L-4 Pneumococcal conjugate vaccine Keith Klugman (USA)
M
 Control of nosocomial infections with limited resources
Speakers
M-1 The impact of antibiotic resistance on nosocomial infection control Paul Thambyah
(Singapore)
M-2 Community- and hospital-acquired methicillin-resistant
Staphylococcus aureus infections in Beijing China		 Yonghong Yang
(P.R. China)
M-3 Ef fective contr ol of nosocomial infections and antimicr obial
resistance: Hong Kong experience		 Seto Wing Hong
(Hong Kong)
M-4 Policies, policies, policies! what antibiotic policies work? Victor Lim (Malaysia)
N
 New antimicrobial agents on the horizon Speakers
N-1 New antibiotics against multi-resistant gram-positive bacteria
 Keryn Christiansen
(Australia)
N-2 New antibiotics against multiresistant gram-negative bacteria
 David Hooper (USA)
N-3 New inhibitors of ribosomal function
 Robert Moellering (USA)
N-4 New antifungal agents Thomas Patterson (USA)
O
 Antibiotic Resistance in Food Animals Speakers
O-1 Antimicrobial resistance in zoonotic pathogens
 Yong Ho Park (Korea)
O-2 National surveillance of antimicrobial resistance in food-producing
 animals in Japan		 Yutaka Tamura (Japan)
O-3 Antibiotic use in animals: implications for human Robin Patel (USA)
 
HOT TOPICS April 29 (FRI) 11:00~12:30
Emerging infectious diseases
Codes Topics Speaker
HT-1 SARS in Singapore: an academic infection control perspective Paul Tambyah (Singapore)
HT-2 Bioterrorism: anthrax and more Bradley Perkins (USA)
HT-3 Avian influenza: asre we ready for pandemic influenza? Michael Osterholm (USA)
 
PLENARY KEYNOTE LECTURES
Codes
 Topics Speaker
Plenary lecture I
April 27 (WED)
11:00~13:00
 PK-1 Strategies against emerging infectious
diseases: US perspectives
 Michael
Osterholm (USA)
PK-2 Asian perspectives on the control
of antimicrobial resistance		 Jae-Hoon Song
(Korea)
PK-3 European perspectives on antibiotic resistance David Livermore
(UK)
Plenary lecture II
April 27 (WED) 16:00~18:00
PK-4 Worldwide overview of antimicrobial resistance
 		Michael Jacobs
(USA)
PK-5 The relationship between virulence and
antmicrobial resistance in bacteria		 Robert Moellering
(USA)
PK-6 Impact of antimicrobial resistance:
clinical and social aspects		 Donald Low
(Canada)
PK-7 Evolution of antimicrobial treatment:
lessons from the last 60 years		 Walter Wilson
(USA)
Plenary lecture III
April 28 (THU) 11:00~12:30
 PK-8 The epidemic of HIV infection - 2005 Merle Sande
(USA)
PK-9 Challenges of antiretroviral therapy Zelalem Temesgen
(USA)
K-10 Global initiatives to reduce the pandemic
situation of HIV/AIDS		 Donald Sutherland
(WHO)
 
 
 
중앙정렬시 스크롤 따라다니는 레이어
About ARFID | Newsletter Archive | Sitemap | Contact us
Copyright ⓒ ANSORP 2008. All Rights Reserved.